Venus Remedies Ltd informed that the Drug Controller General of India (DCGI) has granted its approval for launching its fourth innovative R&D developed product, fixed dose combination drug of latest generation cephalosporin with an amino-glycoside, after completion of its clinical trials and all related studies. This premium product will be launched by Venus for the first time in the world very shortly.

The company is all set to launch this innovative therapy for APE/Cystis fibrosis patients after completion of the multi-centred phase II clinical trials. The commercial launch of this product shall be a boon to the cystis fibrosis patients being the only solution for the treatment of life threatening infections caused by P Aeruginosa / MRSA in these patients. This is a fatal disease with no sure shot treatment as on date and is fast spreading throughout the world.

This new FDC shall be launched under strategic marketing tie-up with leading Indian pharma companies, in the Rs 2 billion domestic market and is expected to be a segment leader within 2 years of its launch. The company has already filed patent applications in 50 countries worldwide, where this product will be registered by the company, for protection of its patent rights after it is launched in the US $2.5 billion global market.